HTFL Stock Analysis: Heartflow, Common Stock | NASDAQ
Health Information Services | NASDAQ, USA | Market Cap: 2.674m USD | 12M Return: 24.9% | US42238D1072 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 24.8M
Qual. Beats: 0
Rev. Trend: 100.0%
Warnings
Tailwinds
Seasonality 1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
HeartFlow, Inc. (NASDAQ: HTFL) is a medical technology company that offers non-invasive software-based solutions for diagnosing and managing coronary artery disease, serving customers in the United States and internationally. Its HeartFlow Platform applies artificial intelligence and computational fluid dynamics to a standard coronary CT angiography scan, producing a personalized 3D model of a patients coronary arteries. The platform is delivered through three core analyses: RoadMap Analysis (anatomic visualization), FFRCT Analysis (functional blood flow assessment), and Plaque Analysis (plaque volume and composition).
The companys offering is positioned as a non-invasive alternative to traditional invasive catheterization for evaluating coronary blockages, addressing coronary artery disease, which is among the most common cardiovascular conditions worldwide. Revenue is generated primarily through a per-scan service model sold to hospitals and cardiology practices rather than through the sale of capital equipment. HeartFlow was incorporated in 2007, is headquartered in San Francisco, California, and went public on NASDAQ in August 2025.
- CMS reimbursement coverage for FFRCT drives procedure volume growth
- Hospital network adoption of Plaque Analysis accelerates platform revenue
- Competition from Cleerly and Elucid intensifies in cardiac AI imaging
| Net Income: -111.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 12.24 > 1.0 |
| NWC/Revenue: 90.80% < 20% (prev 74.34%; Δ 16.46% < -1%) |
| CFO/TA -0.21 > 3% & CFO -71.0m > Net Income -111.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (368.5m) vs 12m ago 477.1% < -2% |
| Gross Margin: 78.06% > 18% (prev 75.62%; Δ 2.44% > 0.5%) |
| Asset Turnover: 72.44% > 50% (prev 73.83%; Δ -1.39% > 0%) |
| Interest Coverage Ratio: -10.10 > 6 (EBIT TTM -101.8m / Interest Expense TTM 10.1m) |
| A: 0.51 (Total Current Assets 211.8m - Total Current Liabilities 38.0m) / Total Assets 344.0m |
| B: -3.24 (Retained Earnings -1.12b / Total Assets 344.0m) |
| C: -0.39 (EBIT TTM -101.8m / Avg Total Assets 264.2m) |
| D: 4.90 (Book Value of Equity 285.7m / Total Liabilities 58.3m) |
| Altman-Z'' = -4.70 = D |
| DSRI: 0.82 (Receivables 35.5m/30.8m, Revenue 191.4m/136.2m) |
| GMI: 0.97 (GM 75.62% / 78.06%) |
| AQI: 2.89 (AQ_t 0.31 / AQ_t-1 0.11) |
| SGI: 1.41 (Revenue 191.4m / 136.2m) |
| TATA: -0.12 (NI -111.8m - CFO -71.0m) / TA 344.0m) |
| Beneish M = -1.80 (Cap -4..+1) = B |
As of August 15, 2026, the stock is trading at USD 42.08 with a total of 9,897,958 shares traded. Over the past week, the price has changed by +46.01%, over one month by +65.08%, over three months by +30.52% and over the past year by +24.90%.
Current recommended Stop Loss: 39.90 (which is 5.2% or 1.3 ATR below the current price).
Heartflow, Common Stock has no consensus analysts rating.
P/S = 13.9713
P/B = 8.865
Revenue TTM = 191.4m USD
EBIT TTM = -101.8m USD
EBITDA TTM = -92.9m USD
Long Term Debt = 20.0m USD (estimated: total debt 26.3m - short term 6.38m)
Short Term Debt = 6.38m USD (from shortTermDebt, last quarter)
Debt = 26.3m USD (from shortLongTermDebtTotal, last quarter) (leases 26.3m already included)
Net Debt = -132.0m USD (calculated: Debt 26.3m - CCE 158.3m)
Enterprise Value = 2.54b USD (2.67b + Debt 26.3m - CCE 158.3m)
Interest Coverage Ratio = -10.10 (Ebit TTM -101.8m / Interest Expense TTM 10.1m)
EV/FCF = -33.11x (Enterprise Value 2.54b / FCF TTM -76.8m)
FCF Yield = -3.02% (FCF TTM -76.8m / Enterprise Value 2.54b)
FCF Margin = -40.11% (FCF TTM -76.8m / Revenue TTM 191.4m)
Net Margin = -58.42% (Net Income TTM -111.8m / Revenue TTM 191.4m)
Gross Margin = 78.06% ((Revenue TTM 191.4m - Cost of Revenue TTM 42.0m) / Revenue TTM)
Gross Margin QoQ = 80.18% (prev 79.51%)
Tobins Q-Ratio = 7.39 (Enterprise Value 2.54b / Total Assets 344.0m)
Interest Expense / Debt = 38.27% (Interest Expense 10.1m / Debt 26.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -80.4m (EBIT -101.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.57 (Total Current Assets 211.8m / Total Current Liabilities 38.0m)
Debt / Equity = 0.09 (Debt 26.3m / totalStockholderEquity, last quarter 285.7m)
Debt / EBITDA = 1.42 (negative EBITDA) (Net Debt -132.0m / EBITDA -92.9m)
Debt / FCF = 1.72 (negative FCF - burning cash) (Net Debt -132.0m / FCF TTM -76.8m)
Total Stockholder Equity = -13.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.32% (Net Income -111.8m / Total Assets 344.0m)
RoE = 830.5% (negative equity) (Net Income TTM -111.8m / Total Stockholder Equity -13.5m)
RoCE = -1.57k% (out of range, set to none) (EBIT -101.8m / Capital Employed (Equity -13.5m + L.T.Debt 20.0m))
RoIC = -26.56% (negative operating profit) (NOPAT -80.4m / Invested Capital 302.8m)
WACC = 14.49% (E(2.67b)/V(2.70b) * Re(14.33%) + D(26.3m)/V(2.70b) * Rd(38.27%) * (1-Tc(0.21)))
Discount Rate = 14.33% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 75.24 | Cagr: 140.2%
[DCF] Fair Price = unknown (Cash Flow -76.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.13 | # QB: 0
Revenue Correlation: 99.97 | Revenue CAGR: 42.10% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.11 | Chg30d=+1.18% | Revisions=-17% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.49 | Chg30d=+1.04% | Revisions=+50% | GrowthEPS=+70.0% | GrowthRev=+30.7%
EPS next Year (2027-12-31): EPS=-0.27 | Chg30d=-3.56% | Revisions=-17% | GrowthEPS=+43.6% | GrowthRev=+23.1%
[Analyst] Revisions Ratio: +8% (up=5, down=4)